



ISPH-0589

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Crooke et al.

Appln. No. 09/920,394

Filed: August 1, 2001

Title: ANTISENSE MODULATION OF
ACYL COENZYME A CHOLESTEROL)
ACYLTRANSFERASE-1
EXPRESSION

) Group Art Unit: 1635

) Examiner: J. Schultz

) May 1, 2003

#160/
R.T.
5/12
I.D.S.
RECEIVED

MAY 09 2003

TECH CENTER 1600/2900

Mail Stop RCE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SECOND INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents listed thereon are enclosed herewith. This Information Disclosure Statement is submitted concurrently with a Request for Continuing Examination application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.

on May 1, 2003.



Signature
TRACY U. PALOVICH

REMARKS

Listed below is a previously filed, and co-pending, US Patent application. This application and the present application are commonly owned:

- (1) US Patent Application No. 09/918,026, filed July 30, 2001, which corresponds with International Patent Application No. PCT/US02/22746 (WO 03/011889).

Listed below are documents cited in the International Search Report corresponding with (1) above, dated December 17, 2002 in the related International Patent Publication No. WO 03/011889, published February 13, 2003. A copy of the Report is enclosed, together with copies of these documents.

- (1) International Patent Publication WO99/67368;
- (2) Japanese patent publication JP0217286(A), for which an English language abstract is also provided as (CG), relates to an acyl-CoA:cholesterol acyltransferase inhibitor containing at least one of the following:
 - (a) a pyrimidine selected from thymine, uracil or cytosine, and/or a purine selected from adenine, guanine or hypoxanthine;
 - (b) a nucleoside selected from adenosine, guanosine, cytidine uridine, thymidine or inosine having one of the above-noted pyrimidine or purine bases; and/or
 - (c) a nucleotide selected from adenylic acid, guanylic acid, cytidylic acid, uridylic acid, thymidylic acid or inosinic acid having one of the above-noted pyrimidine or purine bases.

When blended with additives, the compound is useful in treating hypercholesterolemia or atherosclerosis.

(3) BUHMAN-Resistance to diet-induced hypercholesterolemia and Gallstone formation in ACAT2-deficient mice, Nature Medicine, Vol. 6, No. 12, December 2000

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200